Drugs / Bosmolisib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04018248 | Apr 2020 → Sep 2023 | Waldenstrom macroglobulinemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma +2 | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07180771 | Feb 2026 → Sep 2027 expected | peripheral T-cell lymphoma, not otherwise specified | Boryung Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bosmolisib | “BR101801 (Bosmolisib)” NCT07180771 ↗ |
| Known as | BR101801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04018248 ↗ |
| Modality | Small molecule | — CHEMBL6068044 ↗ |
| Route | Oral | “BR101801 capsules orally” NCT04018248 ↗ |